News tagged with capecitabine
Related topics: breast cancer
Capecitabine (INN) ( /keɪpˈsaɪtəbiːn/) (Xeloda, Roche) is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. The activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouridine (5'-DFUR), to form 5-fluorouracil.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
A phase I clinical trial examining the safety of combining temsirolimus and capecitabine in advanced malignancies suggests the two agents can be given safely to patients. In addition, the Georgetown Lombardi Comprehensive ...
Cancer May 16, 2012 | 5 / 5 (1) | 0
Drug combination shrinks secondary brain tumours in breast cancer without substantial side effects of radiotherapy
The sizeable and increasing proportion of women with advanced breast cancer whose disease has spread to the brain could be effectively treated systemically with a combination of two drugs, sparing them the debilitating neurological ...
Cancer Nov 01, 2012 | 5 / 5 (1) | 0
(HealthDay)—Secondary prophylaxis with diltiazem may offer cancer patients relief from capecitabine-induced chest pain and dyspnea and allow them to tolerate capecitabine treatment, according to a study ...
Cardiology Nov 16, 2012 | 5 / 5 (1) | 0